MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells

Drug Metabolism and Pharmacokinetics

Volumn 31, Issue 3, 2016, Pages 201-209

  Yamashita, Yasunari ^a   Asakura, Mitsutoshi ^a   Mitsugi, Ryo ^a   Fujii, Hideaki ^a   Nagai, Kenichiro ^a   Atsuda, Koichiro ^a   Itoh, Tomoo ^a   Fujiwara, Ryoichi ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

3D culture; DPP 4; Hepatotoxicity; HepG2 cells; miRNA; Vildagliptin

Indexed keywords

MICRORNA; MICRORNA 222; MICRORNA 877; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; NITRILE; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; TOXIC HEPATITIS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL CULTURE TECHNIQUE; DRUG EFFECTS; HEP-G2 CELL LINE; LIVER; METABOLISM;

ADAMANTANE; ANIMALS; CELL CULTURE TECHNIQUES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; MICE, INBRED C57BL; MICRORNAS; NITRILES; PYRROLIDINES;

EID: 84969170221     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.1016/j.dmpk.2016.02.004     Document Type: Article

References (44)

1. A.J. Scheen Pharmacokinetics of dipeptidylpeptidase-4 inhibitors Diabetes Obes Metab 12 2010 648 658
2. C.F. Deacon Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review Diabetes Obes Metab 13 2011 7 18
3. H. He, P. Tran, H. Yin, H. Smith, Y. Batard, L. Wang, and et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans Drug Metab Dispos 37 2009 536 544
4. M. Asakura, M. Nakano, K. Hayashida, H. Fujii, M. Nakajima, K. Atsuda, and et al. Human nitrilase-like protein does not catalyze the hydrolysis of vildagliptin Drug Metab Pharmacokinet 29 2014 463 469
5. M. Asakura, H. Fujii, K. Atsuda, T. Itoh, and R. Fujiwara Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver Drug Metab Dispos 43 2015 477 484
6. T. Karagiannis, P. Boura, and A. Tsapas Safety of dipeptidyl peptidase 4 inhibitors: a perspective review Ther Adv Drug Saf 5 2014 138 146
7. N. Kurita, T. Ito, S. Shimizu, T. Hirata, and H. Uchihara Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient Diabetes Care 37 2014 e198 e199
8. Y.L. He, R. Sabo, J. Campestrini, Y. Wang, G.J. Riviere, J.C. Nielsen, and et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers Br J Clin Pharmacol 65 2008 338 346
9. Y.G. Kim, S. Hahn, T.J. Oh, S.H. Kwak, K.S. Park, and Y.M. Cho Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis Diabetologia 56 2013 696 708
10. J.F. Chen, E.M. Mandel, J.M. Thomson, Q. Wu, T.E. Callis, S.M. Hammond, and et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation Nat Genet 38 2006 228 233
11. C. Blenkiron, L.D. Goldstein, N.P. Thorne, I. Spiteri, S.F. Chin, M.J. Dunning, and et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype Genome Biol 8 2007 R214
12. Y. Zhang, Y. Jia, R. Zheng, Y. Guo, Y. Wang, H. Guo, and et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases Clin Chem 56 2010 1830 1838
13. P.S. Mitchell, R.K. Parkin, E.M. Kroh, B.R. Fritz, S.K. Wyman, E.L. Pogosova-Agadjanyan, and et al. Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci U S A 105 2008 10513 10518
14. T. Yokoi, and M. Nakajima microRNAs as mediators of drug toxicity Annu Rev Pharmacol Toxicol 53 2013 377 400
15. M. Li, Y. Yang, Z.X. He, Z.W. Zhou, T. Yang, P. Guo, and et al. MicroRNA-561 promotes acetaminophen-induced hepatotoxicity in HepG2 cells and primary human hepatocytes through downregulation of the nuclear receptor corepressor dosage-sensitive sex-reversal adrenal hypoplasia congenital critical region on the X chromosome, gene 1 (DAX-1) Drug Metab Dispos 42 2014 44 61
16. M.R. McGill, and H. Jaeschke MicroRNAs as signaling mediators and biomarkers of drug- and chemical-induced liver injury J Clin Med 4 2015 1063 1078
17. K.S. Makarova, N.V. Grishin, S.A. Shabalina, Y.I. Wolf, and E.V. Koonin A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action Biol Direct 1 2006 7
18. R.A. Wilke, D.W. Lin, D.M. Roden, P.B. Watkins, D. Flockhart, I. Zineh, and et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges Nat Rev Drug Discov 6 2007 904 916
19. X. Yang, J. Greenhaw, Q. Shi, Z. Su, F. Qian, K. Davis, and et al. Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity Toxicol Sci 125 2012 335 344
20. C. Braconi, and T. Patel Non-coding RNAs as therapeutic targets in hepatocellular cancer Curr Cancer Drug Targets 12 2012 1073 1080
21. A. Yano, S. Oda, T. Fukami, M. Nakajima, and T. Yokoi Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury Toxicol Lett 228 2014 13 24
22. K. Aritomi, Y. Ishitsuka, Y. Tomishima, D. Shimizu, N. Abe, T. Shuto, and et al. Evaluation of three-dimensional cultured HepG2 cells in a nano culture plate system: an in vitro human model of acetaminophen hepatotoxicity J Pharmacol 124 2014 218 229
23. S.C. Ramaiahgari, M.W. den Braver, B. Herpers, V. Terpstra, J.N. Commandeur, B. van de Water, and et al. A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies Arch Toxicol 88 2014 1083 1095
24. R. Medina, S.K. Zaidi, C.G. Liu, J.L. Stein, A.J. van Wijnen, C.M. Croce, and et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival Cancer Res 68 2008 2773 2780
25. X. Yang, Z. Li, Z. Su, K. Davis, T. Chen, D. Mendrick, and et al. Urinary micrornas as noninvasive biomarkers for acetaminophen-induced liver injury J Postgenom Drug Biomark Dev 1 2011 101
26. X. Huang, J. Qin, and S. Lu Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1 Int J Clin Exp Pathol 8 2015 1515 1524
27. J. Ward, S. Bala, J. Petrasek, and G. Szabo Plasma microRNA profiles distinguish lethal injury in acetaminophen toxicity: a research study World J Gastroenterol 18 2012 2798 2804
28. K. Wang, B. Long, J.Q. Jiao, J.X. Wang, J.P. Liu, Q. Li, and et al. miR-484 regulates mitochondrial network through targeting Fis1 Nat Commun 3 2012 781
29. S. Bala, J. Petrasek, S. Mundkur, D. Catalano, I. Levin, J. Ward, and et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases Hepatology 56 2012 1946 1957
30. A.D. Vliegenthart, J.M. Shaffer, J.I. Clarke, L.E. Peeters, A. Caporali, D.N. Bateman, and et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury Sci Rep 5 2015 15501
31. S.J. Busch, P. Hoffmann, P. Sahota, R. Johnson, W. Kothny, F. Meyer, and et al. Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man Diabetes Obes Metab 15 2013 72 76
32. N.J. Hewitt, and P. Hewitt Phase I and II enzyme characterization of two sources of HepG2 cell lines Xenobiotica 34 2004 243 256
33. S.F. Lan, B. Safiejko-Mroczka, and B. Starly Long-term cultivation of HepG2 liver cells encapsulated in alginate hydrogels: a study of cell viability, morphology and drug metabolism Toxicol In Vitro 24 2010 1314 1323
34. S. Baskerville, and D.P. Bartel Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes RNA 11 2005 241 247
35. F. Ozsolak, L.L. Poling, Z. Wang, H. Liu, X.S. Liu, R.G. Roeder, and et al. Chromatin structure analyses identify miRNA promoters Genes Dev 22 2008 3172 3183
36. F. Momen-Heravi, S. Bala, K. Kodys, and G. Szabo Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS Sci Rep 5 2015 9991
37. J.C. Lee, J.T. Zhao, J. Gundara, J. Serpell, L.A. Bach, and S. Sidhu Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222 J Surg Res 196 2015 39 48
38. D.Q. Feng, B. Huang, J. Li, J. Liu, X.M. Chen, Y.M. Xu, and et al. Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes Asian Pac J Cancer Prev 14 2013 7501 7508
39. B.F. Burkey, P.K. Hoffmann, U. Hassiepen, J. Trappe, M. Juedes, and J.E. Foley Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited Diabetes Obes Metab 10 2008 1057 1061
40. C. Naspinski, X. Gu, G.D. Zhou, S.U. Mertens-Talcott, K.C. Donnelly, and Y. Tian Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage Toxicol Sci 104 2008 67 73
41. Y. Kanno, and Y. Inouye A consecutive three alanine residue insertion mutant of human CAR: a novel CAR ligand screening system in HepG2 cells J Toxicol Sci 35 2010 515 525
42. S. Wilkening, F. Stahl, and A. Bader Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties Drug Metab Dispos 31 2003 1035 1042
43. R. Kostadinova, F. Boess, D. Applegate, L. Suter, T. Weiser, T. Singer, and et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity Toxicol Appl Pharmacol 268 2013 1 16
44. A. Nakamura, M. Nakajima, H. Yamanaka, R. Fujiwara, and T. Yokoi Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines Drug Metab Dispos 36 2008 1461 1464